Waters Corporation (WATERS CORP) - 10-Q Summary
Business Context and Reporting Period
This filing is a Quarterly Report on Form 10-Q for the period ended April 1, 2006. Waters Corporation designs, manufactures, and services analytical instrument systems, including liquid chromatography (LC), mass spectrometry (MS), and thermal analysis instruments. The company operates through two primary divisions: the Waters Division and the TA Instruments Division.
Key Financial Metrics
| Metric | Q1 2006 | Q1 2005 |
|---|---|---|
| Total Net Sales | $290.2 million | $268.3 million |
| Gross Profit | $169.6 million | $156.5 million |
| Gross Margin | 58.4% | 58.3% |
| Operating Income | $59.5 million | $57.9 million |
| Net Income | $44.2 million | $46.6 million |
| Diluted EPS | $0.42 | $0.38 |
| Operating Cash Flow | $78.4 million | $80.5 million |
| Total Debt (Short + Long Term) | $825.0 million | $810.0 million |
| Cash and Equivalents | $481.2 million | $586.9 million |
Material Changes vs. Prior Period
- Revenue Growth: Net sales increased 8% year-over-year. In constant currencies, U.S. sales declined 2%, while European sales grew 26% and Asian sales grew 39% (driven by India and China).
- Accounting Change: The company adopted SFAS No. 123(R) in Q1 2006, recognizing $7.5 million in stock-based compensation expense, compared to negligible expense in the prior year. This reduced operating income and net income.
- Restructuring: The company incurred $4.4 million in restructuring charges related to a cost reduction plan initiated in February 2006, affecting approximately 75 employees.
- Acquisition: Acquired the food safety business of VICAM Limited Partnership for approximately $13.7 million in cash.
- Share Repurchases: Purchased 2.1 million shares for $90.1 million, reducing the number of outstanding shares and supporting EPS growth.
- Interest Expense: Increased significantly to $11.4 million from $4.2 million due to higher debt levels used to fund share repurchases and higher interest rates.
Guidance, Outlook, and Risks
- Outlook: Management expects full-year 2006 stock-based compensation expense to be approximately $31.0 million. Additional restructuring costs of $3.5 million to $4.5 million are expected for the remainder of 2006.
- Product Trends: Strong demand for ACQUITY UPLC and Q-Tof Premier systems. However, sales to large U.S. pharmaceutical accounts remain weak, and MS product sales declined 2% due to this weakness and delays in new product launches.
- Liquidity: The company maintains $481.2 million in cash and $223.4 million in available borrowing capacity under credit facilities. Management believes this is sufficient to fund operations, acquisitions, and share repurchases for the next 12 months.
- Risks:
- Legal Proceedings: A securities class action lawsuit was filed in April 2006 alleging misrepresentation of customer demand. The company intends to defend vigorously.
- Patent Litigation: Ongoing disputes with Agilent/HP regarding patent infringement in Europe. A settlement was reached in the UK for 3.5 million British Pounds, but cases in France and Germany remain pending.
- Market Dependence: Approximately 51% of sales are to the pharmaceutical and biotechnology industries, which are subject to spending fluctuations.
Investor Verification Checklist
- Verify the impact of the new SFAS 123(R) accounting standard on future quarterly earnings and cash flow.
- Monitor the resolution of pending patent litigation in France and Germany and potential additional costs.
- Assess the recovery of sales to large U.S. pharmaceutical customers, which declined 7% in the quarter.
- Track the integration and revenue contribution of the VICAM acquisition.
- Review the progress of the restructuring plan and the realization of projected cost savings ($4.4 million in 2006).